What are the requirements for keytruda patient assistance?

What paperwork is needed to qualify for Keytruda patient assistance?

Merck’s patient-assistance program requires proof of U.S. residency, a valid prescription for Keytruda, and household income at or below 400 percent of the federal poverty level. Applicants must submit a completed enrollment form, recent tax returns or pay stubs, and insurance documentation that shows either no coverage or insufficient coverage for the drug.

How does the Keytruda program handle uninsured versus underinsured patients?

Uninsured patients can receive the drug at no cost if they meet income and residency rules. Underinsured patients whose insurance leaves them responsible for high out-of-pocket costs can also qualify, provided their remaining expenses exceed program limits. The program verifies coverage gaps directly with the insurer before approving assistance.

When does Keytruda patient assistance start and how long does it last?

Once approved, patients typically receive medication within two to four weeks. Coverage continues for twelve months and can be renewed each year with updated income and insurance documents.

What side effects or dosing issues trigger extra paperwork for assistance?

The program does not require extra forms for side effects. Dosing follows the FDA label, so any change in schedule must come from the prescriber on a new prescription or letter of medical necessity.

Are there income or asset tests that can disqualify an applicant?

Only income is reviewed; assets such as home equity or retirement savings are not counted. A patient whose income exceeds 400 percent of the poverty level is ineligible regardless of medical need.

Can a Medicare Part D patient still receive Keytruda through the program?

Medicare Part D enrollees are generally ineligible unless they have spent down to the coverage gap and still face unaffordable costs. The program reviews Explanation of Benefits statements to confirm the gap.

How do biosimilars affect eligibility for Keytruda assistance?

No FDA-approved biosimilar to pembrolizumab (Keytruda) exists yet. If one launches before Keytruda’s patents expire, the assistance program would likely restrict new enrollments to patients for whom the biosimilar is medically inappropriate.

When does Keytruda’s patent protection end and could that change assistance rules?

Keytruda’s primary U.S. composition-of-matter patent expires in 2028, with additional method-of-use patents extending to 2032–2034. Patent expiration could open the market to biosimilars and prompt Merck to adjust program criteria, but current rules remain in place until then.

[1] https://www.drugpatentwatch.com/drug/Keytruda
[2] Merck & Co. Keytruda Patient Assistance Program enrollment materials